FIELD: biotechnology.
SUBSTANCE: invention relates to an isolated polynucleotide encoding a polypeptide containing a chimeric antigen receptor for CD19 (CAR), in which the polypeptide does not contain a rituximab binding site, and wherein the polynucleotide comprises a short EF1a promoter which is capable of expressing a chimeric antigen receptor for CD19 (CAR) in a mammalian T cell, as well as to a vector and a T-cell containing it. Also disclosed is a pharmaceutical composition containing said cell.
EFFECT: invention is effective for treating a disease or disorder associated with high CD19 levels in a subject.
25 cl, 13 dwg, 5 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
| METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
| CELL | 2015 |
|
RU2768019C2 |
| CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
| NEW CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS CONTAINING TNFR2 DOMAINS | 2019 |
|
RU2808254C2 |
| CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | 2014 |
|
RU2727447C2 |
| CELL | 2014 |
|
RU2717984C2 |
| CELL | 2014 |
|
RU2732236C2 |
| COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | 2013 |
|
RU2729401C2 |
